
Keywords: 3- (4،5-سمتیلیتیازول-2-ییل) -2،5-دی فینیل تترازولیم برومید; HCC; hepatocellular carcinoma; CMap; Connectivity Map; MTT; 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; IC50; concentration required to inhibit cell growth by 50%; Drug screening; Support Vector Machines; Hepatocellular carcinoma;